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This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).SUMMARYPluripotent stem cells (PSCs) maintain a low mutation frequency compared with somatic cell types at least in part by preferentially uti-
lizing error-free homologous recombination (HR) forDNA repair.Many endogenousmetabolites causeDNA interstrand crosslinks, which
are repaired by the Fanconi anemia (FA) pathway using HR. To determine the effect of failed repair of endogenous DNA lesions on PSC
biology, we generated iPSCs harboring a conditional FA pathway. Upon FA pathway loss, iPSCs maintained pluripotency but underwent
profound G2 arrest and apoptosis, whereas parental fibroblasts grew normally. Mechanistic studies revealed that G2-phase FA-deficient
iPSCs possess large gH2AX-RAD51 foci indicative of accrued DNA damage, which correlated with activated DNA-damage signaling
throughCHK1. CHK1 inhibition specifically rescued the growth of FA-deficient iPSCs for prolonged culture periods, surprisingly without
stimulating excessive karyotypic abnormalities. These studies reveal that PSCs possess hyperactiveCHK1 signaling that restricts their self-
renewal in the absence of error-free DNA repair.INTRODUCTION
DNA damage caused by endogenous metabolites is a con-
stant threat to the genomic integrity of all cells. Multiple
DNA repair pathways function to identify and repair dam-
age in order to prevent genomic alterations. Embryonic
stem cells (ESCs) are unique among all cell types in that
mutations in their genomes are potentially propagated
throughout the entire organism and germline. It is thought
that for this reason they maintain a lower mutation fre-
quency than somatic cells (Cervantes et al., 2002). Previous
studies have revealed that ESCs accomplish this by
increased scavenging of endogenous sources of DNA dam-
age and increased use of error-free DNA repair pathways,
and by undergoing rapid apoptosis when DNA damage
levels are elevated (Dannenmann et al., 2015; Momcilovic
et al., 2010; Serrano et al., 2011).ManyDNA-damagingme-
tabolites, including reactive oxygen species and aldehydes,
cause DNA interstrand crosslinks (ICLs). The effect of failed
repair of these endogenous lesions on PSC function re-
mains to be explored.
The Fanconi anemia (FA) DNA repair pathway functions
at ICLs to recruit DNA repair effector complexes, which pre-
pare the site for error-free repair by homologous recombi-
nation (HR) (Kim and D’Andrea, 2012). The pathway
consists of a core complex of proteins that serve to identify
sites of damage and activate FANCD2, the central effector
protein that coordinates downstream repair activities.44 Stem Cell Reports j Vol. 6 j 44–54 j January 12, 2016 j ª2016 The AuthorLoss-of-function mutations in FA pathway genes cause an
inherited disorder characterized by bone marrow failure
(BMF) and elevated cancer risk, as well as a myriad of devel-
opmental abnormalities (Auerbach, 2009). Diagnosis of FA
is determined by sensitivity of patient cells to ICL-inducing
agents, such as mitomycin C (MMC), which cause FA cells
to undergo cell-cycle arrest or apoptosis and accumulate
chromosomal abnormalities (Kim and D’Andrea, 2012).
BMF in FA patients is caused by exhaustion of the hemato-
poietic stem and progenitor cells (HSPC) through cell-cycle
arrest and apoptosis (Garaycoechea and Patel, 2013).
Despite the pronounced sensitivity of HSPC to FA
pathway dysfunction, other somatic stem cell populations,
such as those of the skin and intestine, seem unaffected
since their tissues aremaintained normally. A number of re-
ports have suggested that pluripotent stem cells (PSCs) are
especially dependent on the FA pathway. We have noted
previously that both the expression and activity of
FANCD2 is dramatically elevated in normally cycling
PSCs compared with somatic cells (Chlon et al., 2014).
Furthermore, somatic cell reprogramming to induced
pluripotent stem cells (iPSCs) was found to be extremely
inefficient in FA patient cells due to elevated levels of
DNA damage during reprogramming that trigger apoptosis
(Chlon et al., 2014; Muller et al., 2012; Raya et al.,
2009). Stable inhibition of p53 allowed for the derivation
of iPSC colonies from FA patient cells, but these
colonies failed to grow into lines, thus suggesting thats
(legend on next page)
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p53-independent signaling limits the self-renewal of FA
iPSC (Chlon et al., 2014). Despite this, several recent
studies have utilized alternative reprogramming ap-
proaches to successfully derive FA patient iPSCs that could
be passaged (Liu et al., 2014; Muller et al., 2012; Yung et al.,
2013). Others employed short-hairpin RNA (shRNA) or
genome engineering to derive FA-deficient ESCs, and
althoughminor growth defects were reported, FA-deficient
lines were generated and maintained (Liu et al., 2014; Tul-
pule et al., 2010). Nonetheless, an important limitation of
these studies was that reprogramming or genome engineer-
ing require a long clonal growth period during which selec-
tion for optimal growth in the absence of FA might occur.
Thus, these approachesmay underestimate the importance
of the FA pathway for PSC growth. Therefore, we sought a
conditional approachwhereby iPSCs could be derived from
FA-proficient cells but then could be studied as isogenic FA-
proficient and deficient cell lines after reprogramming.
Here, we describe the derivation of patient-derived iPSCs
with inducible complementation of the FA pathway, and
report dramatic phenotypes as a consequence of FA
pathway loss. Our findings establish that the FA pathway
is essential for proliferation and survival of iPSCs and impli-
cates CHK1 as a crucial factor in their extreme sensitivity to
accrued DNA damage.RESULTS
Pluripotent Stem Cells Require the FA Pathway for
Proliferation and Survival
While there have been several reports of PSC hypersensitiv-
ity to exogenous DNA-damaging agents, little is known
about the effect of failed repair of endogenous DNA lesions.
To investigate this, we generated iPSCs from FA patient
cells possessing inducible expression of the complement-
ing FA gene. Somatic cells were isolated from skin biopsies
of two FA patients in the FANCA complementation group
(Figure 1A). These cells were transduced with a lentivirus
expressing the FANCA gene under doxycycline (DOX)-Figure 1. Derivation of iPSC with Inducible Complementation of
(A) Schematic of derivation of iPSC with inducible complementation.
(B) Alkaline phosphatase (AP) staining of reprogramming cultures in
(C and D) Western blot analysis on iPSC formed from FA-A#1 cells and F
larger FANCD2 band, which is the monoubiquitinated form. S indicate
(E and F) IF staining for FANCD2 and gH2AX foci in iPSC treated with
(G and H) IF for OCT-3/4 and NANOG expression. Scale bar, 300 mm.
(I and J) qRT-PCR for expression of POU51 and NANOG relative to H1
(K and L) H&E staining of teratomas derived from iPSC injected into fla
hand panels show immunohistochemistry staining of neighboring sect
teratoma section. Bottom panels are teratomas derived from H1 ESC
d7, day 7.
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sion of FANCA, which reconstituted the functional FA
core complex to monoubiquitinate FANCD2 upon treat-
ment with hydroxyurea (HU) (Figure S1A). In the absence
of DOX, these cells maintained characteristics of FA-defi-
cient cells, including melphalan-induced G2/M arrest and
MMC-induced apoptosis (Figures S1B and S1C). We then
subjected these cells to reprogramming in the presence or
absence of DOX. As expected, only the DOX-treated cells
formed iPS colonies (Figure 1B). Several colonies were
picked and cultured into stable iPS lines in the presence
of DOX. Two independently derived cell lines from each
patient were chosen for further study and were named
FA-A#1 IND iPS1 and 2, and FA-A#2 IND iPS3 and 4.
Once lines were fully established (>10 passages), DOX
was withdrawn from the culture to test the inducible sys-
tem. We confirmed that all lines maintained expression
of FANCA in the presence of DOX, whereas FANCA protein
was no longer detectable in cells 7 days after DOX with-
drawal (DOX) (Figures 1C and 1D). DOX-treated cells
maintained the ability to monoubiquitinate FANCD2 in
response to HU treatment (Figures 1C and 1D) and to
form FANCD2 foci at gH2AX+ sites of DNA damage in con-
trol andMMC-treated cells (Figures 1E and 1F). In contrast,
no monoubiquitinated FANCD2 or FANCD2 foci were
observed inDOX cells (Figures 1E and 1F). Despite exam-
ining >300 cells per iPSC line, FANCD2 DNA repair foci
were never observed in a DOX cell, confirming that the
FA pathway is completely non-functional (Figure S1D).
Importantly, monoubiquitinated FANCD2 and FANCD2
foci were detected in +DOX cells in the absence of a
DNA-damaging agent, indicating that the FA pathway is
active in normal cycling iPSCs (Figures 1C–1F).We assessed
the karyotypes of at least 20 metaphases for all lines and
found no abnormalities in +DOX cells at passages 10 and
40 post derivation, thus suggesting that genome stability
was maintained during iPSC reprogramming and culture
(Figure S1H).
Next, we examined whether FA deficiency had an effect
on pluripotency. Immunofluorescence (IF) detection ofthe FA Pathway
+DOX and DOX media.
A-A#2 cells cultured with or without DOX for 7 days. L indicates the
s the smaller FANCD2 band, which is unmodified.
30 nM MMC for 16 hr. Scale bar, 10 mm.
ESCs.
nks of NSG mice fed DOX chow or regular chow, respectively. Right-
ions for FANCA expression. Inset is a 13magnification of the entire
in NSG mice fed regular chow. Scale bar, 100 mm.
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OCT3/4 and NANOG confirmed that both are highly ex-
pressed in both +DOX and DOX cells (Figures 1G, 1H,
and S1G). We also assessed the expression of the genes
for these proteins, POU5F1 and NANOG, relative to H1
ESCs, and found comparable expression that was unaf-
fected by DOX withdrawal for 7 days (Figures 1I and 1J).
Finally, we tested the ability of these cells to form teratomas
in +DOX and DOX conditions. Cells were pre-treated for
4 dayswith either +DOXorDOXmedia and then injected
into mice fed DOX chow or regular chow, respectively. All
cell lines consistently formed teratomas in both condi-
tions, indicating that pluripotency was unaffected by
DOX withdrawal (Figures 1K, 1L, S1E, and S1F). Impor-
tantly, we confirmed that the teratomas in DOX chow-
fed mice continued to express levels of FANCA similar to
teratomas derived from H1 ESCs while teratomas from reg-
ular chow-fed (DOX) mice did not express FANCA. Thus,
we conclude that loss of the FA pathway does not affect the
pluripotency of iPSCs.
To assess the self-renewal of FA-deficient iPSCs, wemoni-
tored their growth over three passages (15 days) and found
that theDOX cultures underwent progressive exhaustion
(Figures 2A and 2B). EdU staining to monitor the cell cycle
of DOX cultures revealed a profound cell-cycle arrest in
the G2 phase compared with +DOX cultures (Figures 2C
and 2D). Statistically significant G2 arrest with a concomi-
tant reduction in S-phase cells occurred in all cell lines (Fig-
ures 2E and 2F). We then measured the rates of apoptosis
in DOX compared with +DOX cultures and found a 2-
to 4-fold increase in cleaved caspase-3-positive cells, which
was further exacerbated by the addition of 30 nM MMC, a
dose that caused no detectable apoptosis in fibroblasts (Fig-
ures 2G–2J and S1C). Collectively, these data indicate that
iPSC depend on the FA pathway for proliferation and sur-
vival in standard culture conditions.
DNA-Damage Signaling Is Activated in FA-Deficient
iPSCs and Causes Cell-Cycle Arrest
To determine the cause of the exhaustion of FA-deficient
iPSCs, we examined the DNA repair and response activities
in +DOX and DOX cells. First, we detected gH2AX foci,
which mark double-strand breaks (DSBs), in cells at each
stage of the cell cycle. To do this, we co-stained cells with
EdU to label S-phase cells and cyclin B1 (CYCB1) to stain
G2 cells. EdU-negative, CYCB1-negative cells were scored
as G1. While gH2AX foci were almost never observed in
G1-phase iPSCs (<1 per 300 cells), S-phase iPSCs typically
harbored numerous, small gH2AX foci. In contrast, a sub-
set of G2 iPSCs possessed a small number (<5) of large
gH2AX foci (Figure 3A). The percentage of G2 cells with
foci was significantly greater in DOX than in +DOX cul-
tures, indicating that FA-deficient iPSC accrue DSBs in G2
phase (Figures 3B, 3C, and S2A). Next, we co-stained theStemcells for EdU, gH2AX, and RAD51, which is essential for
repair of DSB by HR (Figures 3D–3F). We found that nearly
all gH2AX foci in EdU-negative DOX cells stained
brightly for RAD51, indicating that the HR machinery
was engaged at DSB in the FA-deficient G2 arrested cells.
In total, DOX cells had many more large RAD51 foci
than +DOX cells, suggesting that HR-mediated repair is
stalled in these cells at a stage beyond RAD51 recruitment
(Figures 3E and 3F). Lastly, we co-stained for EdU,
gH2AX, and FANCD2 and found that FANCD2 co-localized
to many gH2AX foci in EdU-negative +DOX cells but not
in DOX cells, indicating that the FA pathway normally
functions at DSB in FA-proficient G2 cells (Figures 3G–3I).
Collectively, these data suggest that iPSCs utilize FA and
HR-mediated repair during the G2 phase of the cell cycle,
and that the inability of FA-deficient iPSCs to repair this
damage likely causes G2 arrest.
To examine the effect of this increased DNA damage in
FA-deficient iPSCs, we measured the activation of DNA-
damage signaling by western blot analysis (Figures 3J,
S2B, and S2C). Increases in the activated forms of the
DNA-damage sensor kinases ATM and ATR were observed,
together with their downstream signal transducers CHK1
and CHK2 in day-7 DOX cells. These were accompanied
by elevated p53 activity and decreased abundance of
CDC25A, which is targeted for degradation by CHK1 and
required for the G2-M phase transition. Thus, we conclude
that DNA-damage signaling is activated in FA-deficient
iPSC, likely causing G2 arrest and apoptosis. Importantly,
this signaling was not activated in DOX cultures of the
parent FA-A#2 fibroblasts (Figure S2D) despite abundant
gH2AX foci in both +DOX andDOXG2-phase fibroblasts
(Figure S2E). Furthermore, the DNA-damage signaling pro-
teins were all expressed at dramatically increased levels in
iPSCswhen comparedwith fibroblasts (Figure S2D). Collec-
tively, these data support the notion that iPSCs have a
heightened DNA-damage response compared with somatic
cells (Dannenmann et al., 2015; Momcilovic et al., 2010),
and indicate that DNA damage accrued from endogenous
sources activates this signaling.
We next sought to determine whether inhibition of
DNA-damage signaling could rescue the growth defects of
FA-deficient iPSC. We first attempted rescue using the
same shRNA against TP53 as in our previous reprogram-
ming study. Western blot and qPCR indicated that p53
was reduced 80% in sh-TP53 cells and that p53 signaling
was significantly repressed (Figures S2F and S2G). However,
we found that sh-TP53 only partially rescued the growth of
the DOX cells (Figures S2H and S2I). Cleaved caspase-3-
positive cells were reduced in sh-TP53-expressing cells in
both +DOX and DOX cultures, indicating a non-specific
decrease in apoptosis (Figures S2J and S2K). In contrast,
sh-TP53 had no effect on the G2 arrest of DOX cellsCell Reports j Vol. 6 j 44–54 j January 12, 2016 j ª2016 The Authors 47
Figure 2. FA Pathway Loss Causes Pro-
gressive Exhaustion of iPSC Cultures
(A and B) AP staining of iPSC cultured with
and without DOX for three passages.
(C and D) EdU cell-cycle analysis of iPSC.
(E and F) Quantification of (C) and (D).
(G and H) Fluorescence-activate cell sorting
(FACS) staining for cleaved caspase-3 on
iPSC treated or untreated with 30 nM MMC
for 24 hr.
(I and J) Quantification of (G) and (H).
d7, day 7. All error bars indicate the stan-
dard deviation of the mean. *Statistical
significance of p < 0.05.(Figures S2L and S2M). These data indicate that p53 does
not affect G2 arrest in FA-deficient cells.
We next sought to identify mechanisms of G2 arrest
induction in FA-deficient iPSCs by screening a series of in-
hibitors targeting DNA-damage response proteins. Inhibi-
tors were first tested for the ability to allow arrested G2
cells in DOX cultures to escape, undergo mitosis, and cy-
cle into G1. To do this, we used a short inhibitor treat-48 Stem Cell Reports j Vol. 6 j 44–54 j January 12, 2016 j ª2016 The Authorment of 2.5 hr, stained for EdU in the last 45 min, and
examined the cell-cycle profile. The ATM inhibitor
KU55933 had no effect on the G2 arrest (Figures 3K and
S2N). The ATR inhibitor ETP-46464 allowed some cells
to escape G2 in a dose-dependent manner (Figures 3K
and S2N), but also caused significant cell death in
both +DOX and DOX cultures (data not shown).
Remarkably, the CHK1 inhibitor AZD7762 (CHK1i)s
(legend on next page)
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allowed full recovery of the DOX G2 cells back to the
same level as +DOX cultures and resulted in an accumula-
tion of G1 cells, which was expected since escaping G2
cells did not have enough time to enter S phase (Fig-
ure 3K). The effect of CHK1i was dose dependent, and
100 nM allowed full recovery of the G2 arrest (Figure S2N).
These data indicate that CHK1 inhibition rescues the G2
arrest of FA-deficient iPSC.
Next, we examined the cells for DSBs after a 2.5 hr treat-
ment with 100 nMCHK1i. As expected, we found an abun-
dance of G1 cells in the CHK1i-treated DOX culture, but
surprisingly these G1 cells possessed gH2AX foci (Fig-
ure 3L), whereas G1 cells in untreated cultures never had
gH2AX foci and few CHK1i-treated +DOX cells had foci
(Figures 3M and 3N). This result suggests that the CHK1i
allows the G2-arrested cells to undergo mitosis without re-
pairing existing DNA damage.
Inhibition of CHK1 Completely Restores Growth of
FA-Deficient iPSC
Based upon the sustained presence of DNA repair foci in
CHK1i-treated FA-deficient cultures, the expectation was
that cellular growth would be limited by the rapid acquisi-
tion of chromosomal damage and consequent cell death.
We thus cultured the FA-inducible iPSCs in CHK1i for a
prolonged period of time. After three passages (15 days)
in DOX conditions, CHK1i fully restored the growth of
theDOX cultures to the same level as +DOX cultures (Fig-
ures 4A and 4B). There was no effect on the growth
of +DOX cells, indicating a specific effect on the growth
of FA-deficient iPSC. CHK1i treatment led to a dramatic in-
crease in the phosphorylation of CHK1-Ser345, and
increased phosphorylation of ATR-Ser428 (Figure 4C). In
contrast, CHK2 activation was unaffected by the CHK1i.
Downstream of CHK1, we found that CDC25A levels
were greatly increased and Ser-15 activation of p53 was
fully attenuated by CHK1i-treatment. These findings are
consistent with decreased G2 arrest and p53-mediatedFigure 3. Unrepaired DNA Damage Causes Cell-Cycle Arrest in FA-
(A) IF on EdU-stained iPSC for gH2AX and CYCB1. CYCB1 marks G2 ce
(B and C) Quantification of the percentage of total cells in G2 with a
(D) IF on EdU-stained iPSC for gH2AX and RAD51.
(E and F) Quantification of RAD51 foci per cell above an empirical th
(G) IF on EdU-stained cells for gH2AX and FANCD2.
(H and I) Quantification of FANCD2/gH2AX double-positive foci and
(J) Western blot on whole-cell lysates from iPSC cultured with and w
(K) iPSC cultured without DOX for 7 days were treated with inhibitors fo
inhibitors that allow G2-arrested cells in DOX cultures to move to G
(L) IF for EdU, gH2AX, and CYCB1 on day-7 DOX iPSC treated with 1
cells.
(M and N) Quantification of the percentage of total cells in G1 with a
d7, day 7. All error bars indicate the standard deviation of the mean.
50 Stem Cell Reports j Vol. 6 j 44–54 j January 12, 2016 j ª2016 The Authorapoptosis, respectively. Cell-cycle and apoptosis analysis
of +DOX and DOX cultures treated with CHK1i for
72 hr revealed a complete recovery of G2 arrest and
apoptosis in both cell lines (Figures 4D–4I and S3A–S3D).
To confirm that inhibition of CHK1 is responsible for the
rescue, we used MK-8776, a selective CHK1 inhibitor, and
found that it also fully rescued the G2 arrest (Figures S3E
and S3F).
To determine the level of genome instability caused by
prolonged CHK1 inhibition, we assessed the karyotypes
of iPSCs grown in the presence and absence of both
DOX and CHK1i for more than 40 days. The DOX un-
treated cells were rarely passaged in order to maintain
enough cells for analysis. The CHK1i-treated +DOX and
DOX cells were passaged every 4 days and grew similarly
to +DOX untreated cells (Figure 4J). From each condition,
20–40 metaphases were scored for both lines, and both
untreated and CHK1i-treated +DOX cells had normal kar-
yotypes (Figure 4K). For the untreated DOX cells, we
observed 2 cells out of 20 with trisomy 12 in the FA-
A#1 iPS1 cells and no abnormalities in the FA-A#2 iPS3
cells. For the CHK1i-treated DOX cells, we observed
trisomies in only 2 cells out of 40 for the FA-A#1 iPSCs,
and translocations in only 1 cell out of 40 on chr4 and
chr5 for the FA-A#2 iPSCs. The absence of profound
karyotypic abnormalities coupled with the stable growth
of CHK1-inhibted iPSCs suggests that other error-free
repair pathways compensate for FA deficiency when
CHK1 is inhibited.DISCUSSION
In this report, we demonstrate that human iPSCs require
the FA pathway for efficient growth in vitro, and establish
CHK1 as a critical regulator of iPSChypersensitivity toDNA
damage. The FA pathway is active in S- andG2-phase iPSCs,
where it likely functions to repair DNA damage caused byDeficient iPSCs through CHK1 Signaling
lls (arrowheads).
nd without gH2AX foci.
reshold.
gH2AX only positive foci in EdU-negative cells.
ithout DOX for 7 days.
r 2.5 hr and pulsed with EdU for the last 45 min. Red arrows indicate
1.
00 nM CHK1i for 2.5 hr. Arrowheads indicate G2 cells and arrows G1
nd without gH2AX foci.
*Statistical significance of p < 0.05. Scale bars, 10 mm.
s
Figure 4. Inhibition of CHK1 Completely Rescues Growth Defects of FA-Deficient iPSC
(A and B) AP staining of iPSC cultured with CHK1i or DMSO for three passages.
(C) Western blot on iPSC treated with 100 nM CHK1i for 72 hr.
(legend continued on next page)
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endogenous sources. Unrepaired damage coincides with
profound G2 arrest and apoptosis in FA-deficient iPSCs,
whereas somatic cell types with greater levels of damage cy-
cle normally. Surprisingly, inhibition of CHK1 completely
and specifically rescues growth of FA-deficient iPSCs
without causing extensive karyotypic abnormalities. This
suggests that CHK1 is abnormally heightened in iPSCs
and that dampening CHK1 activity may be possible
without excessive damage accrual. The risks associated
with CHK1 inhibition must now be assessed in experi-
mental models using methods more sensitive than
karyotyping.
Analysis of DNA-damage foci in CHK1i-treated cells led
to the remarkable discovery that CHK1i allowed FA-defi-
cient iPSCs to escape G2 arrest and undergo mitosis
without repairing the DSBs that had evidently caused their
arrest. A previous study indicates that DSBs arising during
G2-M phase are bound together by the MRN complex to
be repaired after mitosis (Giunta et al., 2010). The damage
is then repaired in G1 by error-prone non-homologous
end-joining (NHEJ) or in the subsequent S phase by HR.
In the CHK1-inhibited iPSCs, HR is unlikely since CHK1
phosphorylation of RAD51 is required for HR (Sorensen
et al., 2005). NHEJ is thus likely to compensate for the FA
pathway, but it is predicted to cause chromosomal translo-
cations, whichwe rarely observed in the FA-deficient iPSCs.
Future studies are necessary to determine whether these or
other repair pathways compensate for FA in CHK1-in-
hibited iPSCs.
A recent report indicates that BRCA1 is required for ICL-
induced activation of CHK1 in FA-deficient cells, indicating
that the engagement of the HRmachinery upstream of the
FA pathway plays a role in checkpoint signaling (Draga
et al., 2015). Correspondingly, we observed that HR pro-
teins were engaged at damage foci in G2-phase FA-deficient
iPSCs by the localization of RAD51. Since iPSCs are so pro-
foundly dedicated to HR-mediated repair, increased BRCA1
activity may contribute to the hypersensitivity of CHK1 in
this cell type.
FA is a complex disease that presents with a myriad of
congenital abnormalities, indicating that FA affects the
development and maintenance of diverse tissues in utero,
including but not limited to the hematopoietic system.(D) EdU cell-cycle analysis of iPSC with and without CHK1i for 72 hr.
(E and F) Quantification of (D).
(G) FACS staining for cleaved caspase-3 on iPSC cultured with CHK1i
(H and I) Quantification of (G). D7, day 7.
(J) AP staining of iPSC cultured with 100 nM CHK1i for 40 days.
(K) Chart indicating karyotypic abnormalities observed in iPSC cultur
40 days. Proportion of metaphases counted with a specific defect ar
counted.
ns, not significant. All error bars indicate the standard deviation of t
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opmental defects is not currently available. The condi-
tional FA iPSC model can now provide an experimental
platform for discovering new drug targets to sustain stem
cell fitness in multiple tissues in the context of FA. CHK1
inhibition is of interest in this regard, given its potential
for stimulating the growth of FA hematopoietic cells (Cec-
caldi et al., 2011) and current clinical use for the targeting
of epithelial tumors, which are common in FA patients.
While CHK1 repression bears a risk of introducing muta-
tions through the abrogation of checkpoint control, a
therapeutic window should now be explored for the use
of CHK1 inhibitors to prevent pre- and post-natal FA
phenotypes.EXPERIMENTAL PROCEDURES
Cell Culture
Patient skin biopsies were obtained from the FA Tissue Repository
at Cincinnati Children’s Hospital (IRB #2008-1331). Patient
keratinocytes and fibroblasts were cultured from fresh skin
punch biopsies as described by Chlon et al. (2014). Biopsy
FA-A#1 was cultured into keratinocytes, and biopsy FA-A#2
was cultured into fibroblasts. pInducer20-FANCA lentiviral
construct was derived by Gateway cloning of the full-length hu-
man FANCA cDNA from a pDONR plasmid (Harvard plasmID)
into pInducer20 (Meerbrey et al., 2011). Keratinocytes or fibro-
blasts were transduced with pInducer20-FANCA and then
selected with G418 for 3 days. For reprogramming, keratinocytes
were transduced with a polycistronic lentivirus expressing OCT-4,
SOX2, KLF4, C-MYC, and RFP (Warlich et al., 2011). Fibroblasts
were reprogrammed by episomal transfection using the Amaxa
system (Lonza) with four plasmids expressing GFP, OCT-4 and
sh-TP53, SOX2 and KLF4, and MYC and LIN28 (Addgene
27082, 27077, 27078, 27080), as described previously (Okita
et al., 2011). At 4 days post-transfection with reprogramming fac-
tors, the cells were plated on irradiated CF-1 MEFs (GlobalStem)
in hESC medium containing 100 ng/ml DOX. After 20 days, col-
onies with characteristic iPSC morphology were picked and trans-
ferred to dishes coated with Matrigel (BD Biosciences) in mTeSR1
(STEMCELL Technologies) with 100 ng/ml DOX. mTeSR1 me-
dium was changed daily and colonies were passaged as needed
(about every 4 days) using Dispase, as described previously
(Chlon et al., 2014). All analyses were done on cells cultured
without DOX for 7 days.or DMSO for 72 hr.
ed with and without DOX, and with and without 100 nM CHK1i, for
e listed in parentheses. Where not indicated, 20 metaphases were
he mean. *Statistical significance of p < 0.05.
s
Immunofluorescence
For IF, cells were fixed, permeabilized, and stained as described pre-
viously (Chlon et al., 2014). Where indicated, 30 nM MMC was
added to the medium 16 hr before fixation. For EdU staining, cells
were incubated with 10 mM EdU for 45 min before fixation. EdU
Click-IT Imaging kits were used following the manufacturer’s in-
structions (Life Technologies) followed by standard IF protocol.
For quantification of IF, >100 cells were counted from three inde-
pendent biological replicates.
Flow Cytometry
For cell-cycle analysis, cells were incubated with 10 mM EdU for
45min before fixation and theClick-it EdUCell Proliferation Assay
kit (Life Technologies) was used for staining. For cleaved caspase-3
staining, PFA-fixed cells were permeabilized and stained with an
Alexa 647-conjugated antibody (Cell Signaling) following the
manufacturer’s protocol.
Teratoma Formation
Teratoma formationwas carried out as described previously inNSG
mice (Chlon et al., 2014). Cells were maintained in either +DOX
orDOXconditions for 4 days before harvesting and thenwere in-
jected into mice fed chow containing DOX or regular chow,
respectively.
Statistics
All pairwise comparisons were examined for statistical significance
by Student’s t test with p < 0.05. Error bars indicate the SD of the
mean for three independent biological replicates.
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